The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

BackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.Method...

詳細記述

書誌詳細

主要な著者:	Hao-Ran Zheng, Ai-Min Jiang, Huan Gao, Na Liu, Xiao-Qiang Zheng, Xiao Fu, Zhi-Ping Ruan, Tao Tian, Xuan Liang, Yu Yao
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2022-09-01
シリーズ:	Frontiers in Oncology
主題:	small cell lung cancer anlotinib chemotherapy real-world data efficacy safety
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!